A collaboration between the Paul Scherrer Institute, CERN's ISOLDE facility, and the Institut Laue-Langevin, has published preclinical study results for a newly developed set of tumour-targeting radiopharmaceuticals. The ...
Dec 24, 2012
0
1
For many years, radioactive iodine which emits beta rays has been used for treatment of thyroid cancer. Generally, 5-year survival rates may exceed 90%. However, some thyroid tumors become resistant to iodine treatment ("iodine-refractory"), ...
Apr 2, 2019
0
1
Dear Mayo Clinic: I have had hyperthyroidism for just over one year, and medication does not seem to keep it in check. I do not want to have my thyroid removed. But I'm nervous about radioactive iodine treatment, which is ...
Dec 7, 2018
0
0
Dear Mayo Clinic: How is thyroid cancer treated? Does it always require taking out the thyroid? When is iodine treatment used, and how does that work?
Mar 21, 2017
0
15
Nearly 44,000 new cases of thyroid cancer will be diagnosed in the U.S. this year, and more than 2,000 people will die of the disease, according to the American Cancer Society.
Oct 2, 2023
0
1
Cancer is often thought of as a disease that affects older people, and with the median age of a cancer diagnosis at 66 years, it does. But cancer can be diagnosed at any age.
Sep 22, 2022
0
21
Women of reproductive age who have thyroid cancer should be cautious about receiving radioactive iodine treatment, which affects their remaining egg supply - their ovarian reserve - and may affect their fertility, new research ...
Apr 3, 2016
0
1
An overactive thyroid gland, or hyperthyroidism, may increase the risk of hospitalization for heart and blood-vessel disease even after surgery to remove the gland, according to a new study. The results will be presented ...
Jun 23, 2012
0
0
(HealthDay) -- Patients with early-stage papillary thyroid cancer (PTC) may benefit from the use of a patient-directed computerized decision aid (DA) to provide medical knowledge and resolve decisional conflicts regarding ...
Jul 6, 2012
0
0
(HealthDay)—U.S. Food and Drug Administration approval for the anti-cancer drug Nexavar (sorafenib) has been expanded to include late-stage differentiated thyroid cancer, the most common type of thyroid cancer.
Nov 24, 2013
0
0
